What's new? Log in Free sign up

Home
Sectors & IndustriesSectors
Earnings
IPOs
Transcripts
Insider
Institutional
Splits

NAVB Dashboard
Financials
Filings
Holdings
Transcripts
ETFs
Insider
Institutional
Shorts
25-NSE Filing

Navidea Biopharmaceuticals (NAVB) 25-NSEExchange delisting

Filed: 16 Jan 24, 1:53pm

Free signup for more

Track your favorite companies
Receive email alerts for new filings
Personalized dashboard of news and more
Access all data and search results

Search this filing

All

Tables only

Footnotes only

Pre-defined:

Table of contents

Filing tables

Export all tables to Excel

Filing exhibits

25-NSE Exchange delisting
99.25 EX-99.25

NAVB similar filings

16 Jan 24 Exchange delisting
23 Oct 23 Exchange delisting

Filing view

Default size S M L
Default font Times Arial

External links

View on EDGAR (sec.gov)

Share this filing

UNITED STATES

OMB APPROVAL

OMB Number:		3235-0080
Expires:	December 31, 2014
Estimated average burden
hours per response:		1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-35076

Issuer:	NAVIDEA BIOPHARMACEUTICALS, INC.
Exchange:	NYSE AMERICAN LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	5600 Blazer Parkway, Suite 200
	Dublin	OHIO	43017-7550
Telephone number:				(614) 793-7500

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Preferred Stock Purchase Rights

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, NYSE AMERICAN LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2024-01-16	By	Nicolas Connolly		Analyst, Regulation
Date		Name		Title

¹	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Resources

Knowledgebase
Log In
Register

Company

About
Contact
Solutions

Products

Deal Roadshow
DealVDR
Evercall
Finsight.com

CapEdge

Earnings Calendar
Earnings Transcripts
EDGAR Filing Screener
IPO Calendar

Compliance
Privacy
Security
Terms

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.